 |
|
|
| |
Evaluation Of The Long-Term Health Outcomes Of Ledipasivir-Sofosbuvir (LDV/SOF) And Sofosbuvir-Based Regimens For Patients With Chronic Hepatitis C And Liver Cirrhosis Across Genotypes 1 To 4
|
| |
| |
".......LDV/SOF was explicitly tested in difficult to treat, protease inhibitor (PI) and peginterferon/
ribavirin (PR)-experienced GT1 patient populations, showing a reduction in HCV progression
of 93% compared with NT[no treatment]. In Treat-Naive GT1, LDV/SOF was associated with a reduction
of liver disease complications by 74% compared to SOF+PR. The SOF regimens
also decreased the incidence of liver disease complications by 87%, 80%, and 67% in
GT2 to GT4 respectively, compared to PR.......Table 5 provides the long term economic outcomes for HCV GT1 to 4 cirrhotic patients."
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Stuart Gordon1, Aijaz Ahmed2, Sammy Saab3, Zobair Younossi4,5
1Henry Ford Hospital, Detroit, MI; 2Stanford University, Stanford, CA; 3University of California Los Angeles, Los Angeles, CA; 4Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA; 5Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA
|
| |
|
|
|
|
|
